BR112012019437A2 - 5-alquinil-pirimidinas - Google Patents
5-alquinil-pirimidinasInfo
- Publication number
- BR112012019437A2 BR112012019437A2 BR112012019437A BR112012019437A BR112012019437A2 BR 112012019437 A2 BR112012019437 A2 BR 112012019437A2 BR 112012019437 A BR112012019437 A BR 112012019437A BR 112012019437 A BR112012019437 A BR 112012019437A BR 112012019437 A2 BR112012019437 A2 BR 112012019437A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidines
- alkynyl
- alkynyl pyrimidines
- medicament
- excessive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Abstract
5-alquinil-pirimidinas. a presente invenção abrange compostos de fórmula geral (1) em pre r^ 1^ a r^ 3^ são como definidos na reivindicação 1, que são adequados para o tratamento de doenças caracterizadas por proliferação celular excessiva ou anormal, e o uso dos mesmo para a preparação de um medicamento tendo as propriedades acima mencionadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10151723 | 2010-01-26 | ||
PCT/EP2011/051061 WO2011092198A1 (en) | 2010-01-26 | 2011-01-26 | 5-alkynyl-pyrimidines |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012019437A2 true BR112012019437A2 (pt) | 2018-03-20 |
Family
ID=42224366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012019437A BR112012019437A2 (pt) | 2010-01-26 | 2011-01-26 | 5-alquinil-pirimidinas |
Country Status (39)
Country | Link |
---|---|
US (3) | US8633183B2 (pt) |
EP (1) | EP2528903B1 (pt) |
JP (1) | JP5746219B2 (pt) |
KR (1) | KR101730933B1 (pt) |
CN (1) | CN102781923B (pt) |
AP (1) | AP3107A (pt) |
AR (1) | AR080020A1 (pt) |
AU (1) | AU2011209344B2 (pt) |
BR (1) | BR112012019437A2 (pt) |
CA (1) | CA2787407C (pt) |
CL (1) | CL2012001821A1 (pt) |
CO (1) | CO6640285A2 (pt) |
CY (1) | CY1118129T1 (pt) |
DK (1) | DK2528903T3 (pt) |
EA (1) | EA027501B1 (pt) |
ES (1) | ES2598230T3 (pt) |
GE (1) | GEP20156229B (pt) |
HK (1) | HK1175175A1 (pt) |
HR (1) | HRP20161308T1 (pt) |
HU (1) | HUE030721T2 (pt) |
IL (1) | IL220674A (pt) |
IN (1) | IN2012DN06602A (pt) |
LT (1) | LT2528903T (pt) |
MA (1) | MA33939B1 (pt) |
ME (1) | ME02511B (pt) |
MX (1) | MX2012008128A (pt) |
MY (1) | MY160241A (pt) |
NZ (1) | NZ601121A (pt) |
PE (1) | PE20121695A1 (pt) |
PL (1) | PL2528903T3 (pt) |
PT (1) | PT2528903T (pt) |
RS (1) | RS55265B1 (pt) |
SG (1) | SG182675A1 (pt) |
SI (1) | SI2528903T1 (pt) |
TN (1) | TN2012000369A1 (pt) |
TW (1) | TWI596093B (pt) |
UA (1) | UA110471C2 (pt) |
UY (1) | UY33199A (pt) |
WO (1) | WO2011092198A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110041536A (ko) | 2008-07-29 | 2011-04-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 5-알키닐-피리미딘 |
AR077280A1 (es) | 2009-06-29 | 2011-08-17 | Incyte Corp | Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden |
US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
AR079529A1 (es) | 2009-12-18 | 2012-02-01 | Incyte Corp | Derivados arilo y heteroarilo sustituidos y fundidos como inhibidores de la pi3k |
UY33199A (es) | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
US8618111B2 (en) * | 2010-01-26 | 2013-12-31 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
WO2011130342A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS |
CA2812526A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
ES2764848T3 (es) | 2010-12-20 | 2020-06-04 | Incyte Holdings Corp | N-(1-(fenilo sustituido)etilo)-9H-purina-6-aminas como inhibidores de PI3K |
US8466162B2 (en) * | 2011-01-26 | 2013-06-18 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyridines |
AU2012212196B2 (en) | 2011-02-02 | 2016-10-13 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels |
US10385070B2 (en) | 2011-02-18 | 2019-08-20 | Vertex Pharmaceuticals Incorporated | Chroman-spirocyclic piperidine amides as modulators of ion channels |
CN103517910B (zh) * | 2011-03-14 | 2016-12-14 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的吗啉-螺环哌啶酰胺 |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
PE20181272A1 (es) | 2011-09-02 | 2018-08-03 | Incyte Holdings Corp | Heterociclilaminas como inhibidores de pi3k |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
AR092211A1 (es) * | 2012-09-24 | 2015-04-08 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de hidropirrolopirrol |
ES2841137T3 (es) | 2013-12-20 | 2021-07-07 | Sagimet Biosciences Inc | Moduladores heterocíclicos de la síntesis de lípidos y combinaciones de los mismos |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
ES2838573T3 (es) | 2014-08-21 | 2021-07-02 | Bristol Myers Squibb Co | Derivados de benzamida ligados como inhibidores potentes de ROCK |
CR20210055A (es) | 2015-02-27 | 2021-04-27 | Incyte Corp | SALES DE IHNIBIDOR DE PI3K Y PROCESOS DE PREPARACIÓN (Divisional 2017-0389) |
CN104803922A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种嘧啶衍生物的制备方法 |
CN104744376A (zh) * | 2015-03-14 | 2015-07-01 | 长沙深橙生物科技有限公司 | 一种2-异丙基嘧啶衍生物的制备方法 |
CN104803921A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种苯取代嘧啶衍生物的制备方法 |
WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
CA3208618A1 (en) * | 2021-01-29 | 2022-08-04 | Louise Clare Kirman | Cdk2 inhibitors and methods of using the same |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3832570A1 (de) | 1988-09-24 | 1990-03-29 | Hoechst Ag | 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte |
JPH08504798A (ja) | 1992-12-18 | 1996-05-21 | ザ ウエルカム ファウンデーション リミテッド | 酵素阻害薬としての,ピリミジン,ピリジン,プテリジノンおよびインダゾール誘導体 |
US5622954A (en) | 1994-05-11 | 1997-04-22 | Fmc Corporation | 5[W(substituted aryl)alkenylene and alkynylene]-2,4-diaminopyrimidines as pesticides |
EP1261327B1 (en) | 2000-02-25 | 2005-04-27 | F.Hoffmann-La Roche Ag | Adenosine receptor modulators |
DE60142236D1 (de) | 2000-07-24 | 2010-07-08 | Krenitsky Pharmaceuticals Inc | Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung |
CN101260104A (zh) * | 2002-08-16 | 2008-09-10 | 阿斯利康(瑞典)有限公司 | 抑制磷酸肌醇3-激酶β |
WO2005016914A1 (en) | 2003-08-14 | 2005-02-24 | Smithkline Beecham Corporation | Chemical compounds |
ATE402705T1 (de) | 2003-12-24 | 2008-08-15 | Astrazeneca Ab | Pyrimidine mit tie2 (tek) aktivität |
JP2006044823A (ja) * | 2004-07-30 | 2006-02-16 | Hitachi Building Systems Co Ltd | 乗客コンベアのハンドレール案内装置 |
WO2006040318A2 (en) * | 2004-10-12 | 2006-04-20 | Applied Research Systems Ars Holding N.V. | Pi3 kinase gamma inhibitors for the treatment of anaemia |
US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
EP1846399A1 (en) | 2005-02-01 | 2007-10-24 | AstraZeneca AB | Pyrimidine compounds having tie2 (tek) inhibitory activity |
US20100048543A1 (en) | 2005-02-01 | 2010-02-25 | Astrazeneca Ab | Pyrimidine compounds having ties (tek) inhibitory activity |
US20070135437A1 (en) | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
WO2006106721A1 (ja) | 2005-03-30 | 2006-10-12 | Shionogi & Co., Ltd. | チロシンキナーゼ阻害作用を有するピリミジン誘導体 |
GB0506467D0 (en) * | 2005-03-31 | 2005-05-04 | Astrazeneca Ab | Compounds |
JP2008534565A (ja) * | 2005-03-31 | 2008-08-28 | アストラゼネカ アクチボラグ | Tie2阻害活性のあるアミノピリミジン誘導体 |
TW200801012A (en) * | 2006-04-26 | 2008-01-01 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
WO2008023180A1 (en) | 2006-08-24 | 2008-02-28 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
ES2523863T3 (es) | 2006-12-29 | 2014-12-02 | Janssen R&D Ireland | Pirimidinas 5,6-sustituidas inhibidoras del VIH |
EP2022785A1 (en) | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
KR20110041536A (ko) * | 2008-07-29 | 2011-04-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 5-알키닐-피리미딘 |
UY33199A (es) * | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
US8618111B2 (en) * | 2010-01-26 | 2013-12-31 | Boehringer Ingelheim International Gmbh | 5-alkynyl-pyrimidines |
-
2011
- 2011-01-24 UY UY0001033199A patent/UY33199A/es not_active Application Discontinuation
- 2011-01-24 US US13/012,082 patent/US8633183B2/en active Active
- 2011-01-25 TW TW100102688A patent/TWI596093B/zh not_active IP Right Cessation
- 2011-01-25 AR ARP110100241A patent/AR080020A1/es active IP Right Grant
- 2011-01-26 SG SG2012054367A patent/SG182675A1/en unknown
- 2011-01-26 CN CN201180011379.0A patent/CN102781923B/zh active Active
- 2011-01-26 CA CA2787407A patent/CA2787407C/en not_active Expired - Fee Related
- 2011-01-26 PE PE2012001055A patent/PE20121695A1/es active IP Right Grant
- 2011-01-26 NZ NZ601121A patent/NZ601121A/en not_active IP Right Cessation
- 2011-01-26 AU AU2011209344A patent/AU2011209344B2/en not_active Ceased
- 2011-01-26 LT LTEP11701130.4T patent/LT2528903T/lt unknown
- 2011-01-26 KR KR1020127022277A patent/KR101730933B1/ko active IP Right Grant
- 2011-01-26 ME MEP-2016-223A patent/ME02511B/me unknown
- 2011-01-26 AP AP2012006360A patent/AP3107A/xx active
- 2011-01-26 PT PT117011304T patent/PT2528903T/pt unknown
- 2011-01-26 BR BR112012019437A patent/BR112012019437A2/pt not_active Application Discontinuation
- 2011-01-26 JP JP2012550424A patent/JP5746219B2/ja active Active
- 2011-01-26 EP EP11701130.4A patent/EP2528903B1/en active Active
- 2011-01-26 HU HUE11701130A patent/HUE030721T2/en unknown
- 2011-01-26 IN IN6602DEN2012 patent/IN2012DN06602A/en unknown
- 2011-01-26 PL PL11701130T patent/PL2528903T3/pl unknown
- 2011-01-26 ES ES11701130.4T patent/ES2598230T3/es active Active
- 2011-01-26 DK DK11701130.4T patent/DK2528903T3/en active
- 2011-01-26 MX MX2012008128A patent/MX2012008128A/es active IP Right Grant
- 2011-01-26 UA UAA201209955A patent/UA110471C2/ru unknown
- 2011-01-26 SI SI201130989A patent/SI2528903T1/sl unknown
- 2011-01-26 GE GEAP201112848A patent/GEP20156229B/en unknown
- 2011-01-26 MA MA35083A patent/MA33939B1/fr unknown
- 2011-01-26 RS RS20160871A patent/RS55265B1/sr unknown
- 2011-01-26 EA EA201201030A patent/EA027501B1/ru not_active IP Right Cessation
- 2011-01-26 WO PCT/EP2011/051061 patent/WO2011092198A1/en active Application Filing
- 2011-01-26 MY MYPI2012003354A patent/MY160241A/en unknown
-
2012
- 2012-06-28 IL IL220674A patent/IL220674A/en active IP Right Grant
- 2012-07-04 CL CL2012001821A patent/CL2012001821A1/es unknown
- 2012-07-23 TN TNP2012000369A patent/TN2012000369A1/en unknown
- 2012-07-27 CO CO12126468A patent/CO6640285A2/es active IP Right Grant
-
2013
- 2013-02-26 HK HK13102374.7A patent/HK1175175A1/zh not_active IP Right Cessation
- 2013-11-22 US US14/087,179 patent/US9321771B2/en active Active
-
2016
- 2016-03-18 US US15/073,795 patent/US20160199383A1/en not_active Abandoned
- 2016-10-10 HR HRP20161308TT patent/HRP20161308T1/hr unknown
- 2016-10-19 CY CY20161101049T patent/CY1118129T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012019437A2 (pt) | 5-alquinil-pirimidinas | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
BR112016028288A2 (pt) | ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto? | |
UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112014021531A8 (pt) | composto, composição farmacêutica e usos dos mesmos | |
BR112015027704A2 (pt) | Composto, uso do mesmo e composição farmacêutica antibacteriana | |
UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
UY31984A (es) | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. | |
MY162604A (en) | Heterocyclic compounds and uses thereof | |
CO6620050A2 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
AU2011274192A8 (en) | Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof | |
TN2011000259A1 (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
EA201101330A1 (ru) | Замещенные пиримидины, предназначенные для лечения рака | |
BR112012029647A2 (pt) | novos derivados de pirimidinas | |
UY32009A (es) | 5-alquinil-pirimidinas | |
BR112014022214A2 (pt) | fenólicos antibacterianos | |
BR112014028991A2 (pt) | triazóis como inibidores de kv3 | |
CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. | |
CO6290768A2 (es) | Tiazolil-dihidro-indazoles | |
CO6460762A2 (es) | 5-alquinil-piridinas | |
BR112012018454A2 (pt) | 5-alquinil pirimidinas e seu uso como inibidores de quinase | |
ECSP11011464A (es) | Tia-triaza-ciclopentazulenos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |